Science is a boon for everyone, especially for those who frequently battle with the severe diseases and health conditions. The ever-increasing medical technology keeps finding ways to prevent humankind from the disastrous diseases. In the same context, researchers have been fortunate to witness the medication for the disorders which haunted a vast number of patients, Migraine.
The chronic migraines attacks can be prevented by this medication and can help to stop the start of constant headaches. A chronic migraine patient undergoes every month in the phase III trial numerous problems such as a headache. The antibody therapy can diminish these issues on a critical inflammatory molecule involved in migraines.
Stephen D Silberstein from the Thomas Jefferson University in the US said that this therapeutic approach gives a new optimism for the migraine patients who are unable to get the treatment with the existing medication. Approximately 127 and 300 million people around the world encounter a chronic migraine and experience more than 15 headaches per month for almost three months, according to the World Health Organization (WHO) estimation.
This diseases can make the patient feel exhausted and yet there are many medications are available to cure the disease but many of those only work before the specified period. Finally, the drug called ‘Fremanezumab’ which is a physiological agent that connects to and blocks the activity of a migraine-associated protein called calcitonin gene-related peptide (CGRP). The compelling results of this drug in migraines led to making the CGRP a focal point of research and drug advancement.
When a migraine attack hits the patient, then the peptide releases at the high levels in response to infection triggers a rapid effect that spurs more CGRP release. The results lead to an excessive consciousness of the brain to pain. The doctors believe that by blocking this peptide the sequence of growing inflammation and prolonged pain sensitivity which causes migraine headaches at many levels; can be broken.
The study was published in the New England Journal of Medicine. For the study, the researchers enlisted 1,130 patients and classified them into three groups. The first team went through the quarterly treatments and the second group underwent one procedure per month where the third team received placebo injections. The experiment continued for 16 weeks, with a treatment window of 12 weeks.
The research results revealed that treatment with ‘fremanezumab’ decreased the number of days on which the patients encountered a headache by an average of 4.3 days with quarterly treatment and 4.6 days with monthly medication. Mr Silberstein said that they saw some cases with 100 percent decrease in a migraine, others with 75 percent decrease. The level of response may vary on patients to patients.
Researchers measured the percentage of patients who had more than a 50 percent decrease in the number of days when they underwent either a critical or a mild headache per month. By this measure, the research team witnessed 37.6 percent of cases on the cyclic regimen, and 40.8 percent on the periodical regimen had at least a 50 percent loss in the number of mild headaches per month, compared to 18.1 percent in the placebo group.